In parallel to InMed’s therapeutic development programs in skin and ocular diseases, InMed is developing a cannabinoid synthesis manufacturing system called IntegraSynTM to produce cost-effective, pharmaceutical-grade, bio-identical cannabinoids. Plant extraction is not feasible to meet long-term pharmaceutical demand of cannabinoid therapeutics, particularly rare cannabinoids. InMed products are designed to be bio-identical to the naturally occurring cannabinoids and the process envisioned to offer cost and time savings, and superior ease, control and quality of manufacturing when compared to alternative methods.

InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:

INM-755, our lead product, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severe genetic skin disorder. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in EB. According to various analyst reports, it is believed that there are an estimated 50,000 EB patients in North America, Europe and Japan;
INM-088 is our product in preclinical development for the treatment of glaucoma, the second leading cause of blindness in the developed world.

InMed Pharmaceuticals Inc. Downloads

InMed - Model INM-755 - Cannabinol Topical Cream for the Treatment of Epidermolysis Bullosa - Brochure